February 06, 2008 – Glenmark Pharmaceuticals Ltd. [Glenmark], announced that its wholly owned Swiss subsidiary Glenmark Pharmaceuticals SA (GSA), has received a milestone of USD 15 Million from
Forest Labs, which is Glenmark’s North American partner for Oglemilast (GRC 3886).
This follows a favourable response from USFDA, allowing Forest to initiate an additional Phase II study in COPD for Oglemilast. Glenmark and Forest Labs are working together closely to initiate additional studies for further longer term development of Oglemilast, including a Phase II study in Asthma...
[PDF] Glenmark Pharmaceuticals' Press Release -
